Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

Table 5 Effect of the tested drugs on the Lactate dehydrogenase-1, Troponin I, and TNFα1 in alloxan-induced diabetic rats

Myocardial biomarkers
Groups	LDH-1 (IU/L)	Troponin I (pg/ml)	TNFα1 (pg/mL)
Normal control group	17.42 ± 0.69	92.12 ± 9.19	06.12 ± 0.45
Diabetic control group	18.50 ± 1.53	95.73 ± 8.23	08.32 ± 0.56
Diabetic group treated with bromocriptine	40.50 ± 10.69^#	313.43 ± 29.43^#	36.56 ± 2.32^#
Diabetic group treated with cabergoline	36.86 ± 12.47^#	143.23 ± 12.93^#	31.20 ± 4.23^#
Diabetic group treated with carpogrelate	19.55 ± 2.20	101.17 ± 8.45	09.74 ± 0.98
Diabetic group treated with bromocriptine + sarpogrelate	27.75 ± 3.91 ^a	241.34 ± 17.83^a	14.84 ± 1.23 ^a
Diabetic group treated with cabergoline + sarpogrelate	34.57 ± 6.60 ^b	128.83 ± 13.53	08.59 ± 0.76 ^b

Values shown are means ± SEM; n = 6 rats per group. # P < 0.05, significantly different from the diabetic control group. a P < 0.05, significantly different from the diabetic group treated with bromocriptine. b P < 0.05, significantly different from the diabetic group treated with cabergoline

ISSN: 2050-6511